RxDoctor Payments Data

Rebecca Rahn, PA

Physician Assistant · Augusta, GANPI 1043548399

Payments from drug & device makers

$363in general payments, 2019–2025

Across 12 payments — averaging $30.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$101
  • EMD Serono, Inc.$99
  • SK Life Science, Inc.$53
  • Bristol Myers Squibb$34
  • Sanofi$23
  • Novartis$23
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed1$101
EMD Serono, Inc.4$99
SK Life Science, Inc.2$53
Bristol Myers Squibb1$34
Sanofi1$23
Novartis1$23
AstraZeneca1$19
Natus Medical Incorporated1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$363 in reported general payments places this provider in the 50th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$10,760
Medicare patients
61
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab43$1,592,223
Kesimpta PenOfatumumab131$1,223,864
ZeposiaOzanimod Hydrochloride29$329,326
TecfideraDimethyl Fumarate33$288,552
AubagioTeriflunomide16$141,169
Rebif RebidoseInterferon Beta-1a/Albumin13$132,907
CopaxoneGlatiramer Acetate19$91,191
Teriflunomide42$38,064
Nurtec OdtRimegepant Sulfate18$28,556
LinzessLinaclotide29$25,346
FingolimodFingolimod Hcl55$22,456
Dimethyl Fumarate39$20,824
MyrbetriqMirabegron24$18,280
KeppraLevetiracetam12$18,149
Dalfampridine ErDalfampridine22$9,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$23$141,16916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →